Amphastar Pharmaceuticals Inc. announced that it has entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for the development and commercialization of a fully synthetic and highly purified human adrenocorticotropic hormone (ACTH) analog, designated AMP-110, in the United States and Canada. Under the agreement, Amphastar will make an upfront payment of $2 million to Hanxin, with potential additional payments of up to $14 million in development milestone payments and up to $75 million in sales milestone payments. Amphastar will also pay Hanxin royalties not to exceed $7.5 million per year and a maximum of $60 million in total. Hanxin will grant Amphastar exclusive rights to AMP-110 intellectual property in the United States and Canada and receive a non-exclusive license from Amphastar for other territories.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1126215) on January 12, 2026, and is solely responsible for the information contained therein.